TTR-mediated amyloidosis

Alnylam Reports Positive Phase II Data for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR), and Initiates Phase III Trial
Yahoo/BusinessWire
Sun, 11/10/13 - 01:08 pm
Alnylam
Patisiran
amyloidosis
TTR-mediated amyloidosis
Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)
Yahoo/BusinessWire
Sun, 06/30/13 - 10:42 am
ALN-TTR02
Alnylam
amyloidosis
TTR-mediated amyloidosis
Isis Pharmaceuticals Launches Trial, Hits Milestone
Motley Fool
Fri, 02/22/13 - 10:39 am
Isis Pharmaceuticals
ISIS-TTR
antisense
GSK
transthyretin amyloidosis
TTR-mediated amyloidosis
Alnylam soars 31% on drug study
Marketwatch
Mon, 07/16/12 - 12:21 pm
Alnylam
ALN-TTR02
TTR-mediated amyloidosis